This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vuylsteke, R.J.C.L.M. Articles by Meijer, S. Search for Related Content PubMed PubMed Citation Articles by Vuylsteke, R.J.C.L.M. Articles by Meijer, S. Social Bookmarking                            What's this?

Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results

R.J.C.L.M. Vuylsteke, P.A.M. van Leeuwen, M.G. Statius Muller, H.A. Gietema, D.R. Kragt, S. Meijer

From the Department of Surgical Oncology, VU University Medical Center, Amsterdam, the Netherlands.

Address reprint requests to S. Meijer, MD, PhD, VU University Medical Center, Department of Surgical Oncology, PO Box 7057, 1007 MB Amsterdam, the Netherlands; email: s.meijer{at}vumc.nl.

Purpose: Although sentinel lymph node (SLN) status is part of the new American Joint Committee on Cancer staging system, there is no final proof that the SLN procedure in melanoma patients influences outcome of disease. This study investigated the accuracy of the SLN procedure and clinical outcome in melanoma patients after at least 60 months of follow-up.

Patients and Methods: Between 1993 and 1996, 209 patients with stage I/II cutaneous melanoma underwent selective SLN dissection by the triple technique. If the SLN contained metastatic disease, a completion lymphadenectomy was performed. Survival analyses were performed using the Kaplan-Meier approach. Factors associated with survival were analyzed using the Cox proportional hazards regression model.

Results: The success rate was 99.5%. Median follow-up was 72 months. Forty patients (19%) had a positive SLN. The false-negative rate was 9%. Five-year overall survival was 87% for the entire group and 92% and 67% for SLN-negative and SLN-positive patients (P < .0001), respectively. All patients with a positive SLN and a Breslow thickness 1.00 mm survived, and SLN-positive patients with a Breslow thickness less than 2.00 mm tend to have a better prognosis compared with SLN-negative patients with a Breslow thickness greater than 2.00 mm. SLN status (P = .002), Breslow thickness (P = .002), and lymphatic invasion (P = .0009) were all found to be independent prognostic factors for overall survival.

Conclusion: With a success rate of 99.5% and a false-negative rate of 9% after long-term follow-up, the triple-technique SLN procedure is a reliable and accurate method. Survival data seem promising, although a therapeutic effect is still questionable. As shown in this study, not all SLN-positive patients have a poor prognosis.

Supported by a grant from the Fritz Ahlqvist Foundation, Aerdenhout, The Netherlands.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Y. Bilimoria, C. M. Balch, J. D. Wayne, D. C. Chang, B. E. Palis, S. M. Dy, and J. R. Lange Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States J. Clin. Oncol., April 10, 2009; 27(11): 1857 - 1863. [Abstract] [Full Text] [PDF]

				J. A.P. Leijte, I. M.C. van der Ploeg, R. A. Valdes Olmos, O. E. Nieweg, and S. Horenblas Visualization of Tumor Blockage and Rerouting of Lymphatic Drainage in Penile Cancer Patients by Use of SPECT/CT J. Nucl. Med., March 1, 2009; 50(3): 364 - 367. [Abstract] [Full Text] [PDF]

				Z. I. Nowecki, P. Rutkowski, and W. Michej The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2-pT3) Ann. Surg. Oncol., August 1, 2008; 15(8): 2223 - 2234. [Abstract] [Full Text] [PDF]

				M. H. Kanzler Lymphatic Mapping and Sentinel Node Biopsy: The Data Unclouded by Speculation--Reply Arch Dermatol, May 1, 2008; 144(5): 688 - 689. [Full Text] [PDF]

				F. Niakosari, H. J. Kahn, D. McCready, D. Ghazarian, L. E. Rotstein, A. Marks, A. Kiss, and L. From Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma Arch Dermatol, April 1, 2008; 144(4): 462 - 467. [Abstract] [Full Text] [PDF]

				V. H. Ho, M. I. Ross, V. G. Prieto, A. Khaleeq, S. Kim, and B. Esmaeli Sentinel Lymph Node Biopsy for Sebaceous Cell Carcinoma and Melanoma of the Ocular Adnexa Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 820 - 826. [Abstract] [Full Text] [PDF]

				B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, B. J.R. Sluijter, P. G.J.T.B. Wijnands, A. Baars, A. J.M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients Clin. Cancer Res., May 15, 2007; 13(10): 2961 - 2969. [Abstract] [Full Text] [PDF]

				T. G. Zogakis, R. Essner, H.-j. Wang, L. J. Foshag, and D. L. Morton Natural History of Melanoma in 773 Patients with Tumor-Negative Sentinel Lymph Nodes Ann. Surg. Oncol., May 1, 2007; 14(5): 1604 - 1611. [Abstract] [Full Text] [PDF]

				Z. I. Nowecki, P. Rutkowski, A. Nasierowska-Guttmejer, and W. Ruka Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma Ann. Surg. Oncol., December 1, 2006; 13(12): 1655 - 1663. [Abstract] [Full Text] [PDF]

				A. van Akkooi, J. de Wilt, C Verhoef, P. Schmitz, A. van Geel, A. Eggermont, and M Kliffen Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann. Onc., October 1, 2006; 17(10): 1578 - 1585. [Abstract] [Full Text] [PDF]

				S. Mocellin, A. Ambrosi, M. C. Montesco, M. Foletto, G. Zavagno, D. Nitti, M. Lise, and C. R. Rossi Support Vector Machine Learning Model for the Prediction of Sentinel Node Status in Patients With Cutaneous Melanoma Ann. Surg. Oncol., August 1, 2006; 13(8): 1113 - 1122. [Abstract] [Full Text] [PDF]

				K. D. Lewis, W. A. Robinson, M. McCarter, N. Pearlman, S. J. O'Day, C. Anderson, T. T. Amatruda, A. Baron, C. Zeng, M. Becker, et al. Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant Melanoma J. Clin. Oncol., July 1, 2006; 24(19): 3157 - 3163. [Abstract] [Full Text] [PDF]

				R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. Clin. Cancer Res., May 1, 2006; 12(9): 2826 - 2833. [Abstract] [Full Text] [PDF]

				J. Vaquerano, W. G. Kraybill, D. L. Driscoll, R. Cheney, and J. M. Kane III American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma Ann. Surg. Oncol., February 1, 2006; 13(2): 198 - 204. [Abstract] [Full Text] [PDF]

				B. G. Molenkamp, R. J.C.L.M. Vuylsteke, P. A.M. van Leeuwen, S. Meijer, W. Vos, P. G.J.T.B. Wijnands, R. J. Scheper, and T. D. de Gruijl Matched Skin and Sentinel Lymph Node Samples of Melanoma Patients Reveal Exclusive Migration of Mature Dendritic Cells Am. J. Pathol., November 1, 2005; 167(5): 1301 - 1307. [Abstract] [Full Text] [PDF]

				T. G. Zogakis, R. Essner, H.-j. Wang, R. R. Turner, Y. T. Takasumi, R. L. Gaffney, J. H. Lee, and D. L. Morton Melanoma Recurrence Patterns After Negative Sentinel Lymphadenectomy Arch Surg, September 1, 2005; 140(9): 865 - 872. [Abstract] [Full Text] [PDF]

				D. R. Berk, D. L. Johnson, A. Uzieblo, M. Kiernan, and S. M. Swetter Sentinel Lymph Node Biopsy for Cutaneous Melanoma: The Stanford Experience, 1997-2004 Arch Dermatol, August 1, 2005; 141(8): 1016 - 1022. [Abstract] [Full Text] [PDF]

				R. J. C. L. M. Vuylsteke, P. J. Borgstein, P. A. M. van Leeuwen, H. A. Gietema, B. G. Molenkamp, M. G. S. Muller, P. J. van Diest, J. R. M. van der Sijp, and S. Meijer Sentinel Lymph Node Tumor Load: An Independent Predictor of Additional Lymph Node Involvement and Survival in Melanoma Ann. Surg. Oncol., June 1, 2005; 12(6): 440 - 448. [Abstract] [Full Text] [PDF]

				J. B. Roaten, N. Pearlman, R. Gonzalez, R. Gonzalez, and M. D. McCarter Identifying Risk Factors for Complications Following Sentinel Lymph Node Biopsy for Melanoma Arch Surg, January 1, 2005; 140(1): 85 - 89. [Abstract] [Full Text] [PDF]

				R. J. C. L. M. Vuylsteke, B. G. Molenkamp, H. A. Gietema, P. A. M. van Leeuwen, P. G. J. T. B. Wijnands, W. Vos, P. J. van Diest, R. J. Scheper, S. Meijer, and T. D. de Gruijl Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma Cancer Res., November 15, 2004; 64(22): 8456 - 8460. [Abstract] [Full Text] [PDF]

				H. Tsao, M. B. Atkins, and A. J. Sober Management of Cutaneous Melanoma N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012. [Full Text] [PDF]

				A. Doubrovsky, J.H.W. de Wilt, R.A. Scolyer, W.H. McCarthy, and J.F. Thompson Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma Ann. Surg. Oncol., September 1, 2004; 11(9): 829 - 836. [Abstract] [Full Text] [PDF]